Skip to main content
Erschienen in: Trials 1/2022

Open Access 22.04.2022 | COVID-19 | Correction

Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion

verfasst von: Sarah Halford, Susan Wan, Ilaria Dragoni, Julie Silvester, Bobojon Nazarov, Daniel Anthony, Suzie Anthony, Emma Ladds, John Norrie, Kevin Dhaliwal, and the CDD SPIKE-1 Project Team

Erschienen in: Trials | Ausgabe 1/2022

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The original article can be found online at https://​doi.​org/​10.​1186/​s13063-021-05461-9.
Correction to: Trials 22, 550 (2021)
https://doi.org/10.1186/s13063-021-05461-9
Following the publication of the original article [1], we were notified that the Flu-iiQ™ table included in the supplementary material of original publication needs to be deleted. The authors were not at liberty to publish the table in full as a number of the items listed are confidential and commercially sensitive. For full details of the Flu-iiQ™ questionnaire please contact Measured Solutions P/L, PO Box 5127, Alphington VIC 3079, Australia (measuredsolution​s.​com.​au).
The original article has been corrected.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
download
DOWNLOAD
print
DRUCKEN
Metadaten
Titel
Correction to: SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion
verfasst von
Sarah Halford
Susan Wan
Ilaria Dragoni
Julie Silvester
Bobojon Nazarov
Daniel Anthony
Suzie Anthony
Emma Ladds
John Norrie
Kevin Dhaliwal
and the CDD SPIKE-1 Project Team
Publikationsdatum
22.04.2022
Verlag
BioMed Central
Schlagwort
COVID-19
Erschienen in
Trials / Ausgabe 1/2022
Elektronische ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-022-06266-0

Weitere Artikel der Ausgabe 1/2022

Trials 1/2022 Zur Ausgabe